NEWS CENTER
News-
Koch Biotechnology (Beijing) passed the PEI evaluation, COVID-19 Antigen Rapid Tests constant help fight the pandemic
Release time:
2022-04-20
Source:
Author:
The COVID-19 Antigen Rapid Test Kit, developed by Koch Biotechnology (Beijing) Co., Ltd. successfully passed the performance evaluation of the Paul-Ehrlich Institut in Germany.
The COVID-19 Antigen Rapid Test Kit, developed by Koch Biotechnology (Beijing) Co., Ltd. successfully passed the performance evaluation of the Paul-Ehrlich Institut in Germany.
The Paul-Ehrlich-Institut (PEI), the Federal Institute for Vaccines and Biomedicines, is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). One of the PEI WHO cooperation centers is for quality assurance for Blood Products and in vitro Diagnostic Devices. Koch Biotechnology (Beijing) Co., Ltd. Passing the the PEI evaluation indicates that the production technology and quality inspection of our company are up to international standards.

According to the performance evaluation of PEI, the COVID-19 Antigen Rapid Test Kits of our company have achieved 88% sensitivity and 100% specificity. The high product performance has made an indispensable contribution to the prevention and control of the pandemic.
recommend News